Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

Weisel, Katja; Majer, Istvan; DeCosta, Lucy; Oriol, Albert; Goldschmidt, Hartmut; Ludwig, Heinz; Campioni, Marco; Szabo, Zsolt; Dimopoulos, Meletios

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2020-08-17T09:58:59Z
dc.date.available	2020-08-17T09:58:59Z
dc.date.issued	2019
dc.identifier.issn	1029-2403
dc.identifier.uri	http://hdl.handle.net/10900/104971
dc.language.iso	en	de_DE
dc.publisher	Taylor & Francis Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1080/10428194.2019.1648806	de_DE
dc.subject.ddc	610	de_DE
dc.title	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200409032300_01663
utue.publikation.seiten	37-46	de_DE
utue.personen.roh	Weisel, Katja
utue.personen.roh	Majer, Istvan
utue.personen.roh	DeCosta, Lucy
utue.personen.roh	Oriol, Albert
utue.personen.roh	Goldschmidt, Hartmut
utue.personen.roh	Ludwig, Heinz
utue.personen.roh	Campioni, Marco
utue.personen.roh	Szabo, Zsolt
utue.personen.roh	Dimopoulos, Meletios
dcterms.isPartOf.ZSTitelID	Leukemia & Lymphoma	de_DE
dcterms.isPartOf.ZS-Issue	1	de_DE
dcterms.isPartOf.ZS-Volume	61	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE